Meet our New Internal Auditor Ronald Dongo is a Certified Public Accountant, a Certified Internal Auditor, and an ISO...
Read More
Executive Director’s Message
Greetings
Our mission is to improve the health status of families infected and affected by HIV/AIDS through research, training, prevention and care.
Announcements
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial
April, 2023
Isoniazid preventive therapy (IPT) initiation during pregnancy was associated with increased incidence of adverse pregnancy outcomes in the TB APPRISE trial. Effects of in utero IPT exposure on infant growth are unknown. Co-author Dr. Deo Wabwire contributes to this analysis of data from the TB APPRISE (IMPAACT P1078) trial in eight countries with high tuberculosis prevalence. Click here to read the article.
Experiences and challenges of using community health worker‑led mechanism in supporting HIV disclosure among adults
living with HIV in heterosexual relationships in the rural Uganda
March 11, 2023
HIV status disclosure among sexual partners is vital in HIV management. Community health workers support HIV disclosure among adults living with HIV in sexual relationships with disclosure difficulties. Dr. Zubair Lukyamuzi writes about the experiences faced in using this model in rural Uganda. Click here to read the article.
Progesterone and prolactin levels in pregnant women living with HIV who delivered preterm and low birthweight infants: A nested casecontrol study
January 23, 2023
Antiretroviral therapy (ART) is associated with high rates of adverse birth outcomes, including preterm birth and low birthweight. Studies suggest that progesterone and prolactin may play important intermediary roles. Click here to read more on this data analysis from the PROMISE trial in an article co-authored by Dr. Maxensia Owor.
HIV genotypic resistance among pregnant women initiating ART in Uganda: a baseline evaluation of participants in the Option B+ clinical trial
December 28, 2022
Pre-treatment HIV drug resistance is a threat to elimination of mother to child HIV transmission and could lead to virological failure among HIV-positive pregnant women. Dr. Alexander Amone et al analyze the genotypic HIV drug resistance (HIVDR) of baseline samples of participants enrolled in the Option B+ clinical trial in Uganda. Click here to read the article.
Our Work
Our Partners
© 2022 MU-JHU Research Collaboration. All rights reserved